EUCTR2009-011621-14-DE进行中（未招募）不适用
A 52-week open label extension study to evaluate the safety and tolerability of AIN457 (anti IL-17 monoclonal antibody) in patients with moderate to severe Crohn’sdisease - n/a
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Key inclusion criteria
- •1. Patients who participate and complete the core CAIN457A2202 study up to and including Visit 11 (end of study), may enter the extension study upon signing informed consent.
- •Full inclusion criteria are presented in sections 5.2.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Key exclusion criteria
- •1. Patients for whom continued treatment with AIN457 is not considered appropriate by the treating physician.
- •2. Patients who were non-compliant or who demonstrated a major protocol violation in the core CAIN457A2202 study.
- •3. Patients who discontinued from the core CAIN457A2202 study before end of study.
- •Full exclusion criteria are presented in section 5.3.
研究者
相似试验
进行中（未招募）
不适用
A 52-week open label extension study to evaluate the safety and tolerability of AIN457 (anti IL-17 monoclonal antibody) in patients with moderate to severe Crohn’sdisease - A2202E1EUCTR2009-011621-14-ATovartis Pharma Services AG72
进行中（未招募）
不适用
A 52-week open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2000 mg/d in the treatment of manic episodes of bipolar I disorderBipolar I disorder, manic and mixed episodesEUCTR2004-000686-35-FIovartis Pharma AG215
进行中（未招募）
不适用
A 52 week open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2500 mg/d in the treatment of manic episodes of bipolar I disorderEUCTR2004-000687-27-ATovartis Pharma AG215
进行中（未招募）
不适用
A 76-week open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1ß monoclonal antibody) in patients with active rheumatoid arthritis - not availableMedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2007-000491-16-BEovartis Pharma Services AG
进行中（未招募）
不适用
A 76-week open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1ß monoclonal antibody) in patients with active rheumatoid arthritis - not availableRheumatoid ArthritisEUCTR2007-000491-16-DEovartis Pharma Services AG200